Literature DB >> 28265817

Risk factors and outcome of levofloxacin-resistant Elizabethkingia meningoseptica bacteraemia in adult patients in Taiwan.

Y-C Huang1, Y-W Huang2, Y-T Lin3,4, F-D Wang1,5, Y-J Chan5,6, T-C Yang2.   

Abstract

Elizabethkingia meningoseptica is an emerging nosocomial pathogen associated with high mortality and inherently resistant to many antimicrobial agents. Levofloxacin has been considered as a therapeutic agent based on in vitro susceptibility. We aim to investigate the risk factors and outcomes for levofloxacin-resistant E. meningoseptica bacteraemia. Adult patients with E. meningoseptica bacteraemia were identified retrospectively in a medical centre in Taiwan from January 2011 to July 2015. These strains were identified by the Vitek2 automated system or matrix-assisted laser desorption-ionization time-of-flight mass spectrometry. We compared clinical features and outcomes of patients with levofloxacin-resistant (MIC >2 μg/mL) and levofloxacin-susceptible (MIC ≤2 μg/mL) E. meningoseptica bacteraemia. A total of 93 patients were identified, including 51 (54.8%) with levofloxacin-resistant E. meningoseptica bacteraemia. The APACHE II score (OR, 1.08; 95% CI, 1.02-1.14; p = 0.008) was the only independent risk factor for levofloxacin-resistant E. meningoseptica bacteraemia. The 14-day mortality for patients with levofloxacin-resistant E. meningoseptica bacteraemia (attributable mortality: 30.7%) was significantly higher than that for patients with the levofloxacin-susceptible strain (56.9% versus 26.2%, p = 0.003). In the multivariate analysis of risk factors for mortality, appropriate definite antibiotic use was the only factor associated with 14-day survival (OR, 0.11; 95% CI, 0.02-0.55, p = 0.007). The levofloxacin-resistant strain was borderline significantly associated with mortality (OR, 3.09; 95% CI, 0.88-10.91, p = 0.079). The early identification of levofloxacin resistance in E. meningoseptica isolates is important to tackle this multi-drug resistance pathogen.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28265817     DOI: 10.1007/s10096-017-2942-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  21 in total

Review 1.  Elizabethkingia meningoseptica: an important emerging pathogen causing healthcare-associated infections.

Authors:  S S Jean; W S Lee; F L Chen; T Y Ou; P R Hsueh
Journal:  J Hosp Infect       Date:  2014-02-25       Impact factor: 3.926

2.  Increasing burden of urinary tract infections due to intrinsic colistin-resistant bacteria in hospitals in Marseille, France.

Authors:  Cédric Abat; Guillaume Desboves; Abiola Olumuyiwa Olaitan; Hervé Chaudet; Nicole Roattino; Pierre-Edouard Fournier; Philippe Colson; Didier Raoult; Jean-Marc Rolain
Journal:  Int J Antimicrob Agents       Date:  2014-11-12       Impact factor: 5.283

3.  Chryseobacterium (Flavobacterium) meningosepticum outbreak associated with colonization of water taps in a neonatal intensive care unit.

Authors:  S N Hoque; J Graham; M E Kaufmann; S Tabaqchali
Journal:  J Hosp Infect       Date:  2001-03       Impact factor: 3.926

4.  Carbapenem resistance in Elizabethkingia meningoseptica is mediated by metallo-β-lactamase BlaB.

Authors:  Lisandro J González; Alejandro J Vila
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

5.  Clinical features, antimicrobial susceptibilities, and outcomes of Elizabethkingia meningoseptica (Chryseobacterium meningosepticum) bacteremia at a medical center in Taiwan, 1999-2006.

Authors:  M-S Hsu; C-H Liao; Y-T Huang; C-Y Liu; C-J Yang; K-L Kao; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-03       Impact factor: 3.267

6.  Genetic-biochemical analysis and distribution of the Ambler class A beta-lactamase CME-2, responsible for extended-spectrum cephalosporin resistance in Chryseobacterium (Flavobacterium) meningosepticum.

Authors:  S Bellais; L Poirel; T Naas; D Girlich; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

Review 7.  Chryseobacterium meningosepticum sepsis complicated with retroperitoneal hematoma and pleural effusion in a diabetic patient.

Authors:  Shou-Wu Lee; Che-An Tsai; Bor-Jen Lee
Journal:  J Chin Med Assoc       Date:  2008-09       Impact factor: 2.743

8.  Clinical and microbiological analysis of Elizabethkingia meningoseptica bacteremia in adult patients in Taiwan.

Authors:  Yi-Tsung Lin; Cheng-Hsun Chiu; Yu-Jiun Chan; Mei-Lin Lin; Kwok-Woon Yu; Fu-Der Wang; Cheng-Yi Liu
Journal:  Scand J Infect Dis       Date:  2009

9.  A Chryseobacterium meningosepticum colonization outbreak in a neonatal intensive care unit.

Authors:  S Maraki; E Scoulica; A Manoura; N Papageorgiou; C Giannakopoulou; E Galanakis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-08-16       Impact factor: 3.267

10.  A Nephrostomy-associated Urinary Tract Infection Caused by Elizabethkingia meningoseptica.

Authors:  Hideharu Hagiya; Hiroko Ogawa; Yusuke Takahashi; Kou Hasegawa; Masaya Iwamuro; Fumio Otsuka
Journal:  Intern Med       Date:  2015-12-15       Impact factor: 1.271

View more
  6 in total

Review 1.  Epidemiology and Characteristics of Elizabethkingia spp. Infections in Southeast Asia.

Authors:  Asdren Zajmi; Jeanette Teo; Chew Chieng Yeo
Journal:  Microorganisms       Date:  2022-04-22

Review 2.  Elizabethkingia Infections in Humans: From Genomics to Clinics.

Authors:  Jiun-Nong Lin; Chung-Hsu Lai; Chih-Hui Yang; Yi-Han Huang
Journal:  Microorganisms       Date:  2019-08-28

3.  Elizabethkingia meningoseptica (Chryseobacterium meningosepticum) bacteraemia: a series of 12 cases at Prince Sultan Military Medical City KSA.

Authors:  F S Aldoghaim; N Kaabia; A M Alyami; M A Alqasim; M A Ahmed; A Al Aidaroos; A Al Odayani
Journal:  New Microbes New Infect       Date:  2019-10-25

4.  Elizabethkingia Intra-Abdominal Infection and Related Trimethoprim-Sulfamethoxazole Resistance: A Clinical-Genomic Study.

Authors:  Ling-Chiao Teng; Jiunn-Min Wang; Hsueh-Yin Lu; Yan-Chiao Mao; Kuo-Lung Lai; Chien-Hao Tseng; Yao-Ting Huang; Po-Yu Liu
Journal:  Antibiotics (Basel)       Date:  2021-02-09

5.  Molecular typing and profiling of topoisomerase mutations causing resistance to ciprofloxacin and levofloxacin in Elizabethkingia species.

Authors:  Ming-Jr Jian; Yun-Hsiang Cheng; Cherng-Lih Perng; Hung-Sheng Shang
Journal:  PeerJ       Date:  2018-09-12       Impact factor: 2.984

6.  Molecular Characteristics and Antimicrobial Susceptibility Profiles of Elizabethkingia Clinical Isolates in Shanghai, China.

Authors:  Leilei Wang; Xuefei Zhang; Dan Li; Fupin Hu; Minggui Wang; Qinglan Guo; Fan Yang
Journal:  Infect Drug Resist       Date:  2020-01-29       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.